Based on the observation that, in patients with NPM1- or IDH2-mutated AML, a negative prognosis was observed in the setting of concomitant signaling gene mutations, NPM1 and IDH2 were considered favorable risk in the absence of NRAS, KRAS, and FLT3-ITD. The gene discussed is KRAS; the disease is acute myeloid leukemia.